Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04777708
Title BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.